Inmaculada Hernandez, PharmD, PhD

Inmaculada (Inma) Hernandez, PharmD, PhD, is an assistant professor at the University of Pittsburgh School of Pharmacy. Her research program is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics, and pharmaceutical policy. Specifically, she is interested in the real-world use and outcomes of oral anticoagulation therapy in stroke prevention in atrial fibrillation; the use of large data sets, advanced data mining techniques, and comparative effectiveness research to predict and compare outcomes of medications; and value-based health insurance and health services delivery.


Using the case of oral contraceptives as an example, I explain the differences between off-label and off-guideline prescription, and explain how the inappropriate use of oral contraceptives could be reduced by the regulation of off-guideline prescription.
2 years ago
Oral contraception, the most widely used contraceptive method in the US, is associated with an increased risk of cardiovascular side effects. Despite increased awareness of this risk over the years, the use of oral contraceptives among women with conditions that place them at high risk for cardiovascular effects is still common.
2 years ago
Despite harsh measures imposed by the Eurogroup, a third bailout is arguably a better scenario from the perspective of access to healthcare in Greece than a potential exit from the Eurozone.
2 years ago
The health coverage of millions of Americans in 34 states was pending upon the Supreme Court decision on the King v Burwell case. Luckily, common sense prevailed and the Supreme Court based its ruling on the original motivation behind the creation of the exchanges rather than on the plain language used in the provision.
2 years ago
The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced risk of hemorrhage
2 years ago
What can the US learn from the UK National Health System? Probably not acute care management, but definitely, primary care and preventive interventions.
2 years ago
Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes.
2 years ago
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST